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ABSTRACT
Leptomeningeal carcinomatosis (LMC) remarkably decreases the quality of life 
of EGFR-mutant lung cancer patients. In contrast to the lesions outside the central 
nervous system (CNS), molecular mechanisms of EGFR tyrosine kinase inhibitor 
(TKI) resistance in CNS lesions including LMC are largely unknown. In this study, we 
established an in vivo imaging model for LMC with EGFR mutant lung cancer cell lines 
harboring an exon 19 deletion in EGFR and evaluated the effect of first generation 
EGFR-TKIs, erlotinib, second generation afatinib, and third generation AZD9291. In 
PC-9/ffluc model, erlotinib treatment slowed the development of LMC. Importantly, 
treatment with afatinib or AZD9291 apparently delayed the development of LMC. 
Moreover, treatment with a higher dose of AZD9291, also associated with inhibited 
phosphorylation of EGFR downstream molecule S6, regressed LMC refractory to the 
aforementioned EGFR-TKI treatments. These observations suggest that the third 
generation EGFR-TKI AZD9291 may be an effective treatment for first or second 
generation EGFR-TKI resistant LMC caused by EGFR-mutant lung cancer.
INTRODUCTION
Central nervous system (CNS) metastasis including 
brain metastasis and leptomeningeal carcinomatosis 
(LMC) often develops in several types of cancers such as 
lung, breast, and renal cancer. It is a grave complication 
that shortens survival and markedly diminishes the 
quality of life of the patients [1]. The epidermal growth 
factor receptor (EGFR)-mutant-lung cancer represents 
10% and 25% of non-small-cell lung cancers (NSCLC) 
in Caucasians and East Asians, respectively [2]. LMC 
develops in patients that have the EGFR mutation more 
often compared with patients without the mutation [3]. 
EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as 
first generation gefitinib/erlotinib and second generation 
afatinib showed remarkable activity in EGFR-mutant lung 
cancer patients with or without CNS metastasis [4, 5, 6]. 
However, EGFR-TKI resistance may eventually develop 
after varying periods of treatment, and approximately one-
third of patients develop CNS metastases after acquisition 
of EGFR-TKI resistance [7–9]. Brain metastases are 
manageable by concomitant use of EGFR-TKI and 
radiation therapy including whole brain irradiation and 
stereotactic radiotherapy [10]. There is, however, no 
established therapy for LMC, which is resistant to first 
and second generation EGFR-TKIs. Therefore, novel and 
effective therapies need to be developed for managing 
LMC in cancer patients.
Third generation EGFR-TKIs such as AZD9291 
and CO-1686 effectively block EGFRs with the T790M 
mutation as well as exon 19 deletion and L858R-sensitive 
mutations, but do not inhibit wild type EGFRs. They have 
also shown clinical efficacy in EGFR-mutant lung cancer 
patients who previously treated with EGFR-TKIs [11, 12]. 
However, the efficacy of third generation EGFR-TKIs on 
CNS metastasis is not well reported in literature.
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 In the present study, we established an in vivo 
imaging model for LMC with an EGFR-TKI sensitive 
EGFR-mutant lung cancer cell lines. Furthermore, we 
evaluated the efficacy of AZD9291 in comparison with 
erlotinib and afatinib in our LMC model. 
RESULTS
Establishment of an in vivo imaging model for 
LMC of EGFR-mutant lung cancer
To establish an LMC model with an EGFR-
mutant lung cancer, we utilized the human EGFR 
mutant lung adenocarcinoma PC-9/ffluc (exon 19 
deletion) [13], HCC827/luc, and H1975/luc cells, which 
were transfected with the fusion gene of luciferase for 
in vivo imaging. EGFR-TKIs such as gefitinib, erlotinib, 
afatinib, and AZD9291 decreased viability of PC-9/
ffluc and HCC827/luc cells (Figure 1A, Supplementary 
Figure 4). On the other hand, only afatinib and AZD9291 
decreased viability of H1975/luc cells (Supplementary 
Figure 1). There was no discernible difference between 
luciferase-gene transfectants and parental cells, in terms of 
sensitivity to EGFR-TKIs. Western blot analysis of PC-9/
ffluc revealed that AZD9291 inhibited phosphorylation 
of EGFR and its downstream molecule S6 in a dose-
dependent manner (Figure 1B). We inoculated PC-9/
ffluc cells into the leptomeningeal space of SHO-SCID 
mice (Figure 2A). PC-9/ffluc cells (more than 1.6 × 103) 
developed LMC in SHO-SCID mice. The survival of 
the recipient mice was shortened in a cell number-
dependent manner (Figure 2B). All mice inoculated with 
2 × 105 PC-9/ffluc cells developed LMC (Figure 2C, 2D) 
and became moribund within 28 days; we used this 
experimental protocol for the following experiments. 
Effect of EGFR-TKIs in the LMC model
We sought to examine the effect of AZD9291 in our 
LMC model, as compared with erlotinib. In preliminary 
experiments with the subcutaneous tumor model, daily 
oral treatment with 25 mg/kg of erlotinib remarkably 
prevented the enlargement of PC-9/ffluc tumors for more 
than 23 days. In the same subcutaneous model, daily oral 
treatment with 6 mg/kg of AZD9291 also prevented the 
enlargement of PC-9/ffluc tumors (Figure 3A). Therefore, 
we determined that 25 mg/kg of erlotinib and 6 mg/kg of 
AZD9291 have equivalent activity in our mouse model. 
In the LMC model with PC-9/ffluc cells, the mice 
in the control group became moribund within 28 days 
after tumor cell inoculation. Daily erlotinib treatment 
(25 mg/kg) remarkably delayed the progression of LMC, 
indicating that this dose of erlotinib was effective against 
LMC, which is consistent with its reported clinical activity 
[15]. Importantly, daily oral treatment with 6 mg/kg 
of AZD9291 further delayed the progression of LMC 
(Figure 3B, 3C). In parallel experiments, HCC827/luc and 
H1975/luc cells developed LMC, and AZD9291 showed 
efficacy against the LMC produced by HCC827/luc and 
H1975/luc cells (Figure 4). These observations clearly 
indicate that in addition to erlotinib, AZD9291 has activity 
against LMC of EGFR-mutant lung cancer. 
Effect of high dose of AZD9291 on LMC after 
acquiring EGFR-TKI resistance
We next sought to examine whether a higher dose 
of AZD9291 showed activity against an erlotinib-resistant 
LMC model. When the mice with progressed LMC by 
PC-9/ffluc cells after continuous treatment with 25 mg/
kg of erlotinib were treated with a high dose of AZD9291 
(25 mg/kg), the LMC was regressed (Figure 5A). The 
high dose-AZD9291 treatment also regressed LMC 
that had progressed after treatment with 6 mg/kg of 
AZD9291 (Figure 5A). Interestingly, phosphorylated S6 
in leptomeningeal cancer cells was suppressed after a high 
dose of AZD9291, as determined by immunofluorescence 
analysis (Figure 5B). This confirmed the efficacy of 
high dose-AZD9291 treatment against LMC. In parallel 
experiments, we obtained similar results with LMC 
models treated with afatinib. Briefly, 5 mg/kg of afatinib, 
which could prevent the enlargement of subcutaneous 
PC-9/ffluc tumors (Figure 6A), slowed the progression of 
LMC. However, after continuous treatment with afatinib, 
LMC in the treated mice progressed. It should be noted 
that the high dose of ADZ9291 (25 mg/kg) could regress 
LMC refractory to afatinib treatment (Figure 6B). 
Toxicity profiles of EGFR-TKIs in vivo
To evaluate the toxicity of EGFR-TKI treatment, we 
measured the body weights of the mice during treatment. 
Treatment with EGFR-TKIs including administration 
of a high dose of AZD9291 did not caused severe body 
weight loss (Supplementary Figures 2, 3, 4). Furthermore, 
we assessed skin damage because AZD9291 has been 
reported to have less activity against wild type EGFR 
compared with mutant EGFRs such as exon 19 deletion, 
and L858R and T790M [15]. Accordingly, expression 
of phosphorylated mitogen-activated protein kinase 
(pMAPK), a downstream molecule of EGFR in normal 
skin, remained present after continuous treatment with 
6 mg/kg of AZD9291, while it was inhibited by the 
continuous treatment with 25 mg/kg of erlotinib or 
5 mg/kg of afatinib (Figure 7). Moreover, inhibition of 
EGFR phosphorylation due to treatment with erlotinib or 
afatinib could be reversed after continuous treatment with 
25 mg/kg of AZD9291. These results strongly suggest that 
AZD9291 at the dose without wild-type EGFR inhibition 
is tolerable and sufficient for controlling LMC refractory 
to first and second generation EGFR-TKIs.
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DISCUSSION
In the present study, we have established an in vivo 
imaging LMC model of EGFR-mutant lung cancer and 
demonstrated that third generation EGFR-TKI, AZD9291, 
can manage LMC in our model.
 A recent study reported promising results with 
AZD9291 treatment (response rate of 51%, and progression 
free survival of 8.2 months) in patients who had 
experienced radiographic progression after administration 
of at least one EGFR-TKI [11]. However, since the effect 
of AZD9291 specifically on CNS lesions including LMCs 
was not reported in the study, the activity of AZD9291 
against LMC was unknown. Here, we clearly showed that 
AZD9291 has potential against EGFR-TKI naïve LMC of 
EGFR-mutant lung cancer cells. In addition, AZD9291 may 
also have activity against LMC which is resistant to first and 
second generation EGFR-TKIs. Based on our preclinical 
evidence, we posit that clinical trials are required to 
evaluate the efficacy of AZD9291 treatment in EGFR-
mutant lung cancer patients with CNS metastasis including 
LMC with or without resistance to other EGFR-TKIs.
The ineffectiveness of EGFR-TKIs on CNS metastasis 
is thought to be due to insufficient penetration of EGFR-
TKIs [5]. This is corroborated by the evidence that shows 
erlotinib, which has better penetration in CNS lesions 
Figure 1: Sensitivity of PC-9/ffluc cells to EGFR-TKIs in vitro. (A) PC-9, and PC-9/ffluc cells (2 × 103 cells per well) were 
incubated with various concentrations of erlotinib, gefitinib, AZD9291, and afatinib for 72 hours. Cell growth was determined by the 
MTT assay. Bars represent SD. (B) PC-9/ffluc cells were incubated with AZD9291 (6, 30, 100 nmol/L) for 24 hours. The cell lysates 
were harvested and phosphorylation of indicated proteins was determined by western blot analysis. Data shown are representative of three 
independent experiments with similar results.
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Figure 2: Leptomeningeal carcinomatosis model with PC-9/ffluc cells. (A) PC-9/ffluc cells were inoculated into the space 
between the external occipital protuberance and first cervical vertebra of SHO-SCID mice. (B) Production of LMC was determined using 
the IVIS imaging system; MST: median survival time; N.R: not reached. (C) Representative imaging of mice immediately after PC-9/ffluc 
cell inoculation. (D) Representative histological images of spinal cord with LMC (x40). The high-power field image of dotted area is shown 
in the lower right corner (x400).
Figure 3: Effect of EGFR-TKI treatment in subcutaneous and LMC models with PC-9/ffluc cells. (A) PC-9/ffluc cells 
were inoculated subcutaneously into SHO-SCID mice (N = 4). Daily oral treatment with erlotinib (25 mg/kg) or AZD9291 (6 mg/kg) was 
given from day 8 until day 30. (B) PC-9/ffluc cells were inoculated into the leptomeningeal space of SHO-SCID mice (N = 5). Daily oral 
treatment with erlotinib (25 mg/kg) or AZD9291 (6 mg/kg) was given from day 5 until day 50. Bars represent SD. (C) Representative 
images of mice treated with or without erlotinib (25 mg/kg) or AZD9291 (6 mg/kg).
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than gefitinib, more effectively treats CNS metastasis 
resistant to gefitinib treatment [14, 16]. However, 
gefitinib is generally effective against EGFR-TKI naïve 
CNS metastasis in EGFR-mutant lung cancer patients, 
even though only 1% of gefitinib penetrates into the 
CNS lesions [4, 5, 16, 17]. These observations suggest 
the involvement of other mechanisms that result in the 
development of marginal resistance to a low concentration 
of EGFR-TKIs in CNS lesions. Unfortunately, we could 
not recover tumor cells from the LMC model. Thus, the 
molecular mechanism by which PC-9/ffluc cells acquire 
resistance to EGFR-TKI treatment remains unknown. 
For LMC resistant to the daily standard EGFR-
TKI treatment, no effective therapy has been established. 
Intermittent high dose EGFR-TKI and EGFR-TKI 
pulse therapy was proposed previously [18]. However, 
recent retrospective studies reported that there was 
no significant difference between the effect of a daily 
standard dose of erlotinib and high dose erlotinib pulse 
therapy on the overall survival of patients [19, 20]. We 
also examined the effect of gefitinib-pulse treatment in 
our LMC model. However, gefitinib-pulse treatment was 
not superior to daily gefitinib treatment in the control 
(Supplementary Figure 5).
Afatinib is an irreversible EGFR-TKI that has 
been approved in many countries including US, EU, and 
Japan. The results of the compassionate-use program 
of afatinib indicate that this drug is equally effective in 
EGFR-mutant lung cancer patients with CNS metastasis 
compared with the patients without CNS metastasis 
Figure 4: Effect of EGFR-TKI treatment in LMC models with HCC827/luc and H1975/luc cells. HCC827/luc and 
H1975/luc cells were inoculated into the space between the external occipital protuberance and first cervical vertebra of SHO-SCID mice. 
(A, B) Production of LMC was determined using the IVIS imaging system; MST: median survival time. (C) The mice inoculated with 
HCC827/luc cells were daily treated with control (N = 3) or AZD9291 (6 mg/kg) (N = 4) from day 18 until day 36. (D) The mice inoculated 
with H1975/luc cells were daily treated with control (N = 3) or AZD9291 (6 mg/kg) (N = 3) from Daily oral treatment with AZD9291 
(6 mg/kg) was given from day 5 until day 22.
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[7]. We found that afatinib at a dose of 5 mg/kg, which 
was almost equivalent to 25 mg/kg of erlotinib against 
subcutaneous tumors with PC-9/ffluc cells, remarkably 
delayed the progression of LMC in our model (Figure 5). 
The clinical efficacy of afatinib on CNS metastasis could 
be replicated in the LMC model, confirming clinical 
relevance of this model. Therefore, our LMC model may 
be useful for testing experimental and novel therapies for 
LMC.
In conclusion, we have established an LMC model 
for EGFR-mutant lung cancer and demonstrated the 
potential of third generation EGFR-TKI AZD9291, on not 
Figure 5: Effect of high dose-AZD9291 treatment after acquisition of EGFR-TKI resistance. (A) After acquisition of 
resistance to treatment with 25 mg/kg of erlotinib (N = 5) or 6 mg/kg of AZD9291 (N = 5), the mice were given daily oral treatment with 
AZD9291 (25 mg/kg) for 8 days. The representative images are shown. (B) Cancer cells from the leptomeningeal space were collected after 
development of erlotinib resistance and high dose-AZD9291 treatment. The cell pellets were subsequently analyzed for S6 phosphorylation 
by immunofluorescence. 
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Figure 6: The efficacy of afatinib and high dose-AZD9291 after afatinib resistance in LMC model. (A) PC-9/ffluc cells 
were inoculated subcutaneously in SHO-SCID mice. Mice were treated with 2.5 mg/kg (N = 5) or 5 mg/kg of afatinib (N = 5). Treatment 
was given daily for 23 days. Tumor volume was measured using calipers on the indicated days. Mean ± SE tumor volumes are shown. 
(B) LMC mice with PC-9/ffluc cells were administered afatinib (5 mg/kg) daily from day 8 until day 50. Luminescence was evaluated as 
total flux (p/s: photons/second). After resistance was acquired to afatinib, the LMC mice were administered AZD9291 (25 mg/kg) once 
daily for 8 days (from day 51 until day 58). Arrow indicates the initiation of the high dose AZD9291 (25 mg/kg) treatment.
Figure 7: The effect of continuous EGFR-TKI treatment on MAPK phosphorylation in normal skin cells. PC-9/ffluc 
cells were inoculated subcutaneously in SHO-SCID mice. Mice were treated daily with 25 mg/kg of erlotinib, 5 mg/kg of afatinib, or 
6 mg/kg of AZD9291 for 50 days. Then, small skin tissues (3 mm × 3 mm) were harvested from the mice (upper panels). The mice were 
further treated with 25 mg/kg of AZD9291 for 8 days, and then small skin tissues (3 mm × 3 mm) were harvested again from them (lower 
panels). Phosphorylated ERK expression in these skin lesions was evaluated by immunohistochemistry. (x400).
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only EGFR-TKI naïve LMC but also EGFR-TKI-refractory 
LMC. Our preclinical evidence suggest therapeutic potential 
of AZD9291 on EGFR-mutant lung cancer patients with 
CNS metastasis including LMC with or without resistance 
to other EGFR-TKIs.
MATERIALS AND METHODS
Cell cultures and reagents
The EGFR-mutant human lung adenocarcinoma 
cell line PC-9 with deletions in EGFR exon 19 (del 
E746_A750) and HCC827, with deletions in EGFR 
exon 19 were purchased from Immuno-Biological 
Laboratories Co. (Gunma, Japan) and the American 
Type Culture Collection (Manassas, VA), respectively. 
H1975 cells, with the L858R/T790M double mutations 
in EGFR, were kindly provided from Drs. Yoshitaka 
Sekido (Aichi Cancer Center Research Institute, Japan) 
and John D. Minna (University of Texas Southwestern 
Medical Center). H1975/luc (JCRB1486) and HCC827/
luc (JCRB1516) cells, which are luciferase transfected 
by Dr. Takashi Murakami (Laboratory of Tumor Biology, 
Takasaki University of Health and Welfare, Takasaki, 
Gunma, Japan), were provided from JCRB cell Bank 
(Osaka, Japan). PC-9 ffLuc-cp156 transfectant (PC-9/
ffluc) was established as previously described [13]. 
These cells were maintained in RPMI-1640 medium 
supplemented with 10% fetal bovine serum (FBS) and 
antibiotics. All cells were passaged for less than 3 months 
before renewing frozen, early-passage stocks. Cells were 
regularly screened for mycoplasma contamination using 
MycoAlert Mycoplasma Detection Kits (Lonza, Rockland, 
ME). The cell lines were authenticated at the laboratory of 
the National Institute of Biomedical Innovation (Osaka, 
Japan) by short tandem repeat analysis in May 2015. 
Gefitinib, erlotinib, afatinib, and AZD9291 were obtained 
from Selleck Chemicals (Houston, TX).
Cell viability assay
Cell viability was measured by the MTT dye 
reduction method. Tumor cells were plated at a density 
of 2 × 103/100 μl per well in RPMI 1640 plus 10% FBS 
in 96-well plates and incubated for 24 hours. EGFR-
TKIs were then added to each well, and incubation was 
continued for another 72 hours. Cell growth was measured 
with MTT solution (2 mg/mL; Sigma, St. Louis, MO), as 
described [21].
Western blot
Protein aliquots of 25 μg each were resolved 
by SDS polyacrylamide gel (Bio-Rad, Hercules, CA) 
electrophoresis and transferred to polyvinylidene 
difluoride membranes (Bio-Rad). After washing thrice, 
the membranes were incubated with Blocking One 
(Nacalai Tesque, Inc., Kyoto, Japan) for 1 hour at 
room temperature and then incubated overnight at 4°C 
with primary antibodies against β-Actin, phospho-S6 
(240/244), S6, phospho-EGFR (Y1068;Cell Signaling 
Technology, Beverly, MA), and human EGFR (R & D 
Systems, Minneapolis, MN). Subsequently, the membranes 
were washed thrice again, and incubated for 1 hour at room 
temperature with species-specific horseradish peroxidase–
conjugated secondary antibodies. Immunoreactive 
bands were visualized with SuperSignal West 
Dura Extended Duration Substrate, an enhanced 
chemiluminescent substrate (Pierce Biotechnology, 
Rockford, IL). Each experiment was performed at least 
three times, independently.
Tumor cell inoculation in severe combined 
immunodeficiency (SHO-PrkdcscidHrhr) mice
We used 6-week-old female SHO-PrkdcscidHrhr mice 
(SHO-SCID mice: Charles River, Yokohama, Japan) for 
the study. For the subcutaneous tumor model, cultured 
tumor cells (PC-9/ffluc; 3 × 106 cells/0.1 ml) were 
implanted subcutaneously into the flanks of each mouse. 
For the leptomeningeal metastasis model, the scalp was 
sterilized with 70% ethanol, and the cultured tumor cells 
were injected into the leptomeningeal space (between the 
external occipital protuberance and first cervical vertebra) 
with a 27G needle. 
The size of subcutaneous tumors and body weights 
of the mice were measured twice per week, and tumor 
volume was calculated in mm3 (width2 × length/2). After 8 
days, the mice were either left untreated or treated orally 
with gefitinib, erlotinib, afatinib, or AZD9291. 
This study was carried out in strict accordance with 
the recommendations of the Guide for the Care and Use 
of Laboratory Animals by the Ministry of Education, 
Culture, Sports, Science, and Technology in Japan. The 
protocol was approved by the Committee on the Ethics of 
Experimental Animals and the Advanced Science Research 
Center, Kanazawa University, Kanazawa, Japan (approval 
no. AP-153499). All surgeries were performed on mice 
anesthetized with sodium pentobarbital, and efforts were 
made to minimize the suffering of the animals.
Luciferase expression and radiographic analyses 
with the IVIS imaging system
After inoculation, the quantity of tumors was tracked 
in live mice by repeated noninvasive optical imaging of 
tumor-specific luciferase activity using the IVIS Lumina 
XR Imaging System (PerkinElmer, Alameda, CA). 
Twenty minutes after an intraperitoneal injection of the 
luciferase substrate luciferin (150 mg/kg), the mice were 
photographed under bright-field illumination and images 
were overlaid with luminescence data gathered over the 
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maximum exposure period (5–30 seconds) in anesthetized 
by 2% isofluorane. The intensity of the bioluminescence 
signal was analyzed using Living Image 4.0 (PerkinElmer) 
by serially quantifying peak photon flux at the selected 
region of interest (ROI) covering the tumor. This was 
corrected for total area of ROI and time lapse during which 
the bioluminescence signals were picked by the CCD 
camera and expressed as photo/s/cm2/sr. 
Immunofluorescence
Mice brains harvested from mice inoculated 
with PC-9/ffluc cells into the leptomeningeal space 
were washed with PBS, and tumor cells was collected 
in a tube. The tubes were centrifuged at 800 rpm for 
15 minutes and cell pellets were subsequently analyzed 
for S6 phosphorylation. Immunofluorescence analysis was 
performed as described earlier [22]. Briefly, cells on cover 
slips were fixed in 1% paraformaldehyde for 15 minutes, 
followed by treatment with 0.2% Triton X-100 on ice 
for 20 minutes. The coverslips were then incubated with 
rabbit phosphor S6 (240/244) antibody (Cell Signaling) 
overnight at 4°C, followed by incubation for 1 hour with 
Alexa 488-conjugated goat anti-rabbit (Molecular Probes). 
Confocal microscopy analysis was performed using an 
Olympus fluorescence microscope (Olympus, Japan).
Immunohistochemistry of skin tissue samples
Phospho-p44/42 MAPK (Erk1/2, Thr202/Tyr204, 
Rabbit monoclonal antibody) was purchased from Cell 
Signaling Technology. Peroxidase-based immunohistochemistry 
detection system [EnVision+ System-HRP, Rabbit (DAB+)], 
antibody diluent, and serum-free protein block were 
purchased from Dako. Formalin-fixed paraffin-embedded 
tissue skin sections were subjected to antigen retrieval 
and endogenous peroxidase blocking, and were incubated 
with primary antibody overnight at 4°C. Following 
overnight incubation, slides were rinsed and incubated 
with a peroxidase-labeled polymer. The tissue sections 
were then rinsed and stained with 3,3′-diaminobenzidine 
(DAB) substrate-chromogen and then counterstained with 
Hematoxylin Gill I (EMD Millipore) and bluing reagent 
(EMD Millipore).
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